Bert joined Pappas Capital in 2020 and brings significant experience in translational biomedical research and biotechnology equity research. Prior to joining Pappas, he spent two years at RBC Capital Markets in New York City as a Senior Associate on an Institutional Investor-ranked equity research team covering large-, mid- and small-cap biotechnology companies. At RBC he gained experience building and maintaining financial models, vetting public and private biotechnology companies to support investment banking, and conducted clinical and commercial diligence to shape investment theses. Prior to RBC, Bert was Associate Professor of Medicine at the University of Virginia (UVA) where he established an independent research laboratory investigating the role of the immune system in different forms of kidney disease. Throughout his 10 years at UVA, his laboratory was consistently funded by the NIH, including R01, R21, K01 and F32 grants focused on the role of regulatory T cells in acute kidney injury. His academic experience included in vitro and in vivo preclinical experimentation, as well as translational clinical research in cardiac surgery patients.

Bert currently serves as an observer for CuraSen, OrphoMed and Ribometrix, and previously served as an observer for Reneo Pharmaceuticals.


Medical University of South Carolina (PhD in Pharmaceutical and Biomedical Sciences)
Medical University of South Carolina (Doctor of Pharmacy/PharmD)